食管癌根治性放疗剂量研究进展

doi:10.3760/cma.j.cn113030-20181215-00630

Abstract
Figure/Table
References(35)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (742 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Concurrent chemoradiotherapy is widely accepted as the standard treatment for locally advanced inoperable esophageal cancer, and 50.0 to 50.4Gy is recommended as the optimal dose for definitive treatment by the international guidelines. However, esophageal cancer in China is quite different from that in western countries in terms of the pathological type and biological characteristics, and a radiation dose of 60Gy is recommended. Whether dose-escalated radiotherapy could bring survival benefits remains to be urgently resolved. Some scholars indicate that the higher radiation dose is correlated with better local tumor control and more favorable survival outcomes, whereas others hold the view that increased toxicity and no survival benefits have been observed in the high dose arm. Therefore, this review is to evaluate the impact caused by different radiation doses and assess the clinical efficacy, aiming to individualize the radiation dose.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhao Jingjing
	Pang Qingsong
	Wang Ping

Key words： Esophageal neoplasm/radiotherapy Radiation dose Prognosis

Received: 15 December 2018

Corresponding Authors: Wang Ping, Email:wangping@tjmuch.com

Cite this article:

Zhao Jingjing,Pang Qingsong,Wang Ping. Research progress on radical radiation dose for esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(7): 589-592.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20181215-00630 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I7/589

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[3] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. Jama, 1999, 281(17):1623-1627. DOI:10.1001/jama.281.17.1623.
[4] Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122(ECOG PE-289, RTOG 90-12):Phase Ⅱ trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus[J]. Int J Radiat Oncol Biol Phys, 1999, 43(3):517-523. DOI:10.1016/s0360-3016(98)00463-5.
[5] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J]. J Clin Oncol, 2002, 20(5):1167-1174. DOI:10.1200/jco.2002.20.5.1167.
[6] Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J]. Cancer, 2012, 118(10):2632-2640. DOI:10.1002/cncr.26586.
[7] Nicolini G, Ghosh-Laskar S, Shrivastava SK, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3Dconformal radiotherapy for advanced esophageal cancer:a feasibility study[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2):553-560. DOI:10.1016/j.ijrobp.2011.12.041.
[8] 王鑫, 王澜, 陈俊强, 等. 多中心食管鳞癌根治性三维放疗的预后分析——3JECROG R-01[J]. 中华放射肿瘤学杂志, 2018, 27(11):959-964. DOI:10.3760/cma.j.issn.1004-4221.2018.11.002.
[9] Brower JV, Chen S, Bassetti MF, et al. Radiation dose escalation in esophageal cancer revisited:a contemporary analysis of the national cancer data base, 2004 to 2012[J]. Int J Radiat Oncol Biol Phys, 2016, 96(5):985-993. DOI:10.1016/j.ijrobp.2016.08.016.
[10] De B, Rhome R, Doucette J, et al. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer:a National Cancer Data Base (NCDB) analysis[J]. Dis Esophagus, 2017, 30(4):1-10. DOI:10.1093/dote/dow037.
[11] Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer:a phase 2 trial (KDOG 0501-P2)[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4):872-879. DOI:10.1016/j.ijrobp.2014.03.030.
[12] Fletcher GH. Clinical dose response curves of human malignant epithelial tumours[J]. Br J Radiol, 1973, 46(542):151.
[13] Suh YG, Lee IJ, Koom WS, et al. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages Ⅱ-Ⅲ esophageal cancer[J]. Jpn J Clin Oncol, 2014, 44(6):534-540. DOI:10.1093/jjco/hyu047.
[14] Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction:evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system[J]. Ann Surg, 2011, 253(4):689-698. DOI:10.1097/SLA.0b013e31821111b5.
[15] Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis[J]. Ann Oncol, 2009, 20(2):231-238. DOI:10.1093/annonc/mdn622.
[16] Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer:lessons from more than 1,000 consecutive resections at a single center in the Western world[J]. Ann Surg, 2001, 234(3):360-369. DOI:10.1097/00000658-200109000-00010.
[17] Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?[J]. Semin Radiat Oncol, 2007, 17(1):38-44. DOI:10.1016/j.semradonc.2006.09.007.
[18] Bollschweiler E, Holscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer[J]. Future Oncol, 2010, 6(1):25-35. DOI:10.2217/fon.09.133.
[19] He L, Allen PK, Potter A, et al. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma[J]. J Thorac Oncol, 2014, 9(9):1398-1405. DOI:10.1097/jto.0000000000000267.
[20] Kim HJ, Suh YG, Lee YC, et al. Dose-response relationship between radiation dose and loco-regional control in patients with stage Ⅱ-Ⅲ esophageal cancer treated with definitive chemoradiotherapy[J]. Cancer Res Treat, 2017, 49(3):669-677. DOI:10.4143/crt.2016.354.
[21] 任雪姣, 王澜, 韩春, 等. 食管癌同期放化疗不同放疗剂量远期疗效分析[J]. 中华放射肿瘤学杂志, 2017, 26(9):1006-1011. DOI:10.3760/cma.j.issn.1004-4221.2017.09.006.
[22] Ren X, Wang L, Han C, et al. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma[J]. Radiother Oncol, 2018, 129(2):293-299. DOI:10.1016/j.radonc.2018.09.006.
[23] Song T, Liang X, Fang M, et al. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer:a systematic review and pooled analysis[J]. Expert Rev Anticancer Ther, 2015, 15(10):1157-169.
[24] Chang CL, Tsai HC, Lin WC, et al. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma[J]. Radiother Oncol, 2017, 125(1):73-79. DOI:10.1016/j.radonc.2017.08.025.
[25] Chen CY, Li CC, Chien CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis[J]. Radiother Oncol, 2016, 120(1):136-139. DOI:10.1016/j.radonc.2016.04.042.
[26] Welsh J, Palmer MB, Ajani JA, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):468-474. DOI:10.1016/j.ijrobp.2010.10.023.
[27] Welsh JW, Seyedin SN, Allen PK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer:interim results from a prospective phase Ⅰ/Ⅱ trial[J]. J Thorac Oncol, 2017, 12(2):375-382. DOI:10.1016/j.jtho.2016.10.013.
[28] Chen J, Guo H, Zhai T, et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer:a phase Ⅱ study[J]. Oncotarget, 2016, 7(16):22711-22719. DOI:10.18632/oncotarget.8050
[29] Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer[J]. Radiat Oncol, 2014, 9:191. DOI:10.1186/1748-717x-9-191.
[30] Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 80(4):996-1001. DOI:10.1016/j.ijrobp.2010.03.003.
[31] Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials[J]. J Clin Oncol, 2014, 32(5):385-391. DOI:10.1200/jco.2013.51.2186.
[32] Ott K, Blank S, Becker K, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor[J]. Langenbecks Arch Surg, 2013, 398(2):239-249. DOI:10.1007/s00423-012-1039-0.
[33] van Rossum PSN, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer:a systematic review and meta-analysis[J]. Gastrointest Endosc, 2016, 83(5):866-879. DOI:10.1016/j.gie.2015.11.026.
[34] Uberoi GS, Uberoi AS, Bhutani MS. Endoscopic and imaging predictors of complete pathologic response after chemoradiation for esophageal cancer[J]. Curr Gastroenterol Rep, 2017, 19(11):57. DOI:10.1007/s11894-017-0594-5.
[35] Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO):a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI:10.1016/s1470-2045(18)30201-8.